Page last updated: 2024-08-23

amikacin and pa 824

amikacin has been researched along with pa 824 in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's5 (62.50)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S1
Dufková, I; Hrabálek, A; Karabanovich, G; Klimešová, V; Němeček, J; Pávek, P; Roh, J; Smutný, T; Stolaříková, J; Vávrová, K; Vejsová, M; Vicherek, P1
Dušek, J; Hrabálek, A; Huszár, S; Jand'ourek, O; Karabanovich, G; Klimešová, V; Kočová Vlčková, H; Konečná, K; Konyariková, Z; Korábečný, J; Korduláková, J; Kučera, T; Mikušová, K; Pávek, P; Pávková, I; Pavliš, O; Roh, J; Savková, K; Stolaříková, J; Vávrová, K1
Mabhula, A; Singh, V1
Chauffour, A; Jarlier, V; Ji, B; Lefrançois, S; Robert, J; Truffot, C1
Aguilar-Ayala, DA; Cnockaert, M; Gonzalez-Y-Merchand, J; Martin, A; Palomino, JC; Vandamme, P1
Laughon, BE; Lee, SFK; Lipman, M; McHugh, TD1
Nambiar, S; Schumann, K; Walinsky, S1

Reviews

2 review(s) available for amikacin and pa 824

ArticleYear
Drug-resistance in
    MedChemComm, 2019, Aug-01, Volume: 10, Issue:8

    Topics:

2019
New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease.
    Current opinion in pulmonary medicine, 2019, Volume: 25, Issue:3

    Topics: Amikacin; Anti-Bacterial Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Liposomes; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Oxazoles

2019

Other Studies

6 other study(ies) available for amikacin and pa 824

ArticleYear
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:4

    Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen

2007
1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.
    European journal of medicinal chemistry, 2014, Jul-23, Volume: 82

    Topics: Antineoplastic Agents; Antitubercular Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; HeLa Cells; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitrobenzenes; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured

2014
Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
    Journal of medicinal chemistry, 2019, 09-12, Volume: 62, Issue:17

    Topics: Alcohol Oxidoreductases; Antitubercular Agents; Bacterial Proteins; Dinitrobenzenes; Dose-Response Relationship, Drug; Drug Development; Hydrocarbons, Fluorinated; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Triazoles

2019
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:6

    Topics: Acetamides; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Foot; In Vitro Techniques; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Nitroimidazoles; Oxazolidinones; Quinolines; Rifampin; Streptomycin; Survival Analysis; Time Factors

2006
Antimicrobial activity against Mycobacterium tuberculosis under in vitro lipid-rich dormancy conditions.
    Journal of medical microbiology, 2018, Volume: 67, Issue:3

    Topics: Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Drug Tolerance; Fluoroquinolones; Genetic Fitness; Genotype; Humans; Lipid Metabolism; Lipids; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin

2018
FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs.
    Clinical pharmacology and therapeutics, 2021, Volume: 109, Issue:4

    Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Cross Infection; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Liposomes; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Nitroimidazoles; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sisomicin; United States; United States Food and Drug Administration

2021